血清肿瘤标志物检测在评估NSCLC化疗疗效中的应用价值

目的 探讨血清肿瘤标志物检测在评估非小细胞肺癌(Non-small cell lung cancer,NSCLC)化疗疗效时的应用价值。方法 选择2019年1～11月在我院呼吸科收治的晚期非小细胞肺癌患者30例作为研究对象,设为观察组,所有患者均经过组织病理学检查确诊,且患者均行化疗治疗,对于鳞癌患者给予吉西他滨联合顺铂(Gemcitabine/cisplatin,GP)化疗方案,对于非鳞癌患者给予培美曲塞联合卡铂(Pemetrexed/Carboplatin,PC)方案化疗,疗程完毕后从完全缓解(Complete response,CR)、部分缓解(Complete response,PR)、疾病进展(Progressive disease,PD)、疾病稳定(Stable disease,SD)评估患者近期疗效。选择该时间段体检人群30例设为对照组。检测两组血清同源蛋白2(Anterior gradient 2,AGR2)、可溶性白细胞介素-2受体(Soluble interleukin-2 receptor,SIL-2R)水平、胸苷腺酶1(Thymidine kinase 1,TK1)水平、癌胚抗原(Carcinoembryonic antigen,CEA)、糖类抗原19-9(Glucoprotein antigen 199,CA19-9)及血清癌抗原125(Glucoprotein antigen 125,CA125)水平;并分析血清肿瘤标志物与患者预后的相关性。结果 观察组患者AGR2、SIL-2R、TK1、CEA、CA19-9及CA125水平均高于对照组(P0.05);观察组患者均顺利完成疗程内化疗,化疗后患者AGR2、SIL-2R、TK1、CEA、CA19-9及CA125水平均低于化疗前(P0.05);观察组患者不同疗效下CR+PR率为43.33%,PD+SD率为56.56%。观察组CR+PR患者AGR2、SIL-2R、TK1、CEA、CA19-9及CA125水平均低于PD+SD患者(P0.05);晚期非小细胞肺癌患者化疗预后与AGR2、SIL-2R、TK1、CEA、CA19-9及CA125水平呈负相关(P0.05)。结论 检测晚期非小细胞肺癌患者血清肿瘤标志物对患者的疗效和预后有一定的预测意义。

The application value of serum tumor marker detection in evaluating the efficacy of NSCLC chemotherapy

Objective To explore the application value of serum tumor marker detection in evaluating the efficacy of non-small cell lung cancer(NSCLC) chemotherapy.Methods Thirty patients with advanced non-small cell lung cancer admitted to the Department of Respiratory Medicine of our hospital from January to November 2019 were selected as the observation group.All patients were diagnosed by histopathological examination and all patients received chemotherapy treatment.Patients with squamous cell carcinoma were given Gemcitabine/Cisplatin(GP) chemotherapy,and patients with non-squamous cell carcinoma were given Pemetrexed/Carboplatin(PC) chemotherapy.The short-term efficacy of patients was assessed in terms of complete response(CR),partial response(PR),progressive disease(PD),stable disease(SD) after the course of treatment.Thirty patients with physical examination at this time period were selected as the control group.Serum homologous protein 2 (anterior gradient 2,AGR2),soluble interleukin-2 receptor (SIL-2R) levels,and thymidine kinase 1(TK1),Carcinoembryonic antigen(CEA),Glucoprotein antigen 199(CA19-9) and Glucoprotein antigen 125(CA125) levels between the two groups were detected.The correlation of serum tumor markers and patient prognosis was analyzed.Results The levels of AGR2,SIL-2R,TK1,CEA,CA19-9 and CA125 in the observation group were higher than those in the control group(P<0.05).The patients in the observation group all successfully completed the intra-therapy chemotherapy.The levels of AGR2,SIL-2R,TK1,CEA,CA19-9 and CA125 in the patients after chemotherapy were lower than those before chemotherapy(P<0.05).The CR+PR rate of the observation group was 43.33% and the PD+SD rate was 56.56%.The levels of AGR2,SIL-2R,TK1,CEA,CA19-9,and CA125 in CR+PR patients of the observation group were lower than those in PD+SD patients(P<0.05).The prognosis of chemotherapy was negatively correlated with AGR2,SIL-2R TK1,CEA,CA19-9 and CA125 levels in patients with advanced non-small cell lung cancer(P<0.05).Conclusion The detection of serum tumor markers in patients with advanced non-small cell lung cancer has a certain predictive significance for the efficacy and prognosis of patients.